WO2025191451 - IMIDAZOLINONE DERIVATIVE FOR USE IN THE TREATMENT OF TUMORS IN COMBINATION WITH RDC
National phase entry is expected:
Publication Number
WO/2025/191451
Publication Date
18.09.2025
International Application No.
PCT/IB2025/052558
International Filing Date
10.03.2025
Title **
[English]
IMIDAZOLINONE DERIVATIVE FOR USE IN THE TREATMENT OF TUMORS IN COMBINATION WITH RDC
[French]
DÉRIVÉ D'IMIDAZOLINONE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE TUMEURS EN COMBINAISON AVEC UN MRP
Applicants **
KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD.
Inventors
WEI, Yonggang
SUN, Yi
YE, Fei
Priority Data
202410273774.5
11.03.2024
CN
202410295753.3
15.03.2024
CN
202410376693.8
29.03.2024
CN
202411058175.8
02.08.2024
CN
202411332885.5
24.09.2024
CN
202411379711.4
30.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2869 | |
| EPO | Filing, Examination, Granting | 16023 | |
| Japan | Filing, Examination, Granting | 2607 | |
| South Korea | Filing, Examination, Granting | 3054 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
31,093
Contact Us
Abstract[English]
The present invention provides the use of a compound represented by general formula (I), in combination with RDC, in a drug for use in the treatment of a cancer (I).[French]
La présente invention concerne l'utilisation d'un composé représenté par la formule générale (I), en combinaison avec un MRP, dans un médicament destiné à être utilisé dans le traitement d'un cancer (I).